Co-Diagnostics (CODX) has a debt-to-equity ratio of 0.13, below the Healthcare sector average of 0.34.
Get informed when a big investor buys or sells
+ Follow0.13
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
The latest debt-to-equity ratio for CODX is 0.13. That is below the Healthcare sector average of 0.34. Investors often review this figure alongside Co-Diagnostics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CODX currently prints 0.13 for debt-to-equity ratio, while the sector average sits near 0.34. That is roughly 63.0% below the sector mean. Large gaps often invite a closer look at Co-Diagnostics's growth, margins, and balance sheet.
A debt-to-equity ratio of 0.13 for Co-Diagnostics is not 'good' or 'bad' on its own. Compare it with the peer average (0.34) and with CODX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting CODX's debt-to-equity ratio (0.13), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Co-Diagnostics's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.